Ipsen announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc.
[Ipsen]
Home Newsletters Mesenchymal Cell News Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Brought to you by
